Lymphangioleiomyomatosis: 2026 so far

Evidence shifted toward multi-organ outcomes, not just spirometry.

In the months covered, a larger routine-care cohort linked sirolimus with generally stable lung function over about 5 years. The same report described clearer improvements outside the lungs. These included resolution of chylous effusions (lymphatic fluid leaking into the chest) by 12 months, and decreased angiomyolipoma/lymphangioleiomyoma volumes on paired imaging. Earlier in 2026, a retrospective comparison (a look back at existing medical records) suggested lower sirolimus trough concentrations (the lowest blood level before the next dose) had similar FEV1 change (forced expiratory volume in 1 second, a common breathing test) to conventional targets, without safety differences reported in that summary. Case reports showed mixed experiences. Some individuals were described as stable long-term on sirolimus, while one severe TSC-LAM case worsened after abrupt stopping and improved again after restarting (without full return to prior levels). Taken together, the months covered suggest sirolimus effects may look different depending on what is measured (lungs vs lymphatic/tumor findings), and that dose/level targets and the impact of interruptions are still uncertain in non-randomized evidence.

Research covered in: January 2026, March 2026, May 2026, June 2026, August 2026, September 2026

Management focus expanded from lungs to function and fatigue.

In June, an evidence review (a structured summary of prior studies) found structured exercise programs most consistently increased 6-minute walk distance (a timed walking test of functional capacity), by about 37 meters when a case report was excluded. In the pooled results, changes in FEV1 (forced expiratory volume in 1 second, a common breathing test) and quality of life were not statistically significant. No serious adverse events were reported in these programs. In August, a small comparison study reported that women with LAM had weaker muscles, lower endurance, and more fatigue than matched controls. In that study, muscle endurance tracked with walking distance and peak exercise performance. Muscle biopsies (a small sample of muscle tissue) did not show obvious LAM cell involvement. The same study linked lower fat burning during moderate exercise with worse fatigue scores in the LAM group. In the months covered, these reports connect fatigue and day-to-day physical capacity to measurable muscle performance, even when standard lung tests do not clearly change.

Research covered in: June 2026, August 2026

Case reports detailed varied pleural fluid patterns and targeted procedures.

In September, multiple case reports described complex pleural fluid problems (fluid around the lungs), including chylothorax (lymphatic fluid in the pleural space) and loculated effusions (fluid trapped in separate pockets). These were described as major drivers of symptoms, and management was tailored to the fluid's cause and structure. One post-transplant report described contrast-enhanced ultrasound (an ultrasound using contrast to better show spaces and flow) guiding targeted urokinase injection (a clot-busting medicine) into separate fluid pockets. This was followed by improved drainage and full lung re-expansion after further drainage and repeat pleurodesis (a procedure to help prevent fluid or air from coming back), with no recurrence reported at three weeks. Earlier case reports also linked LAM presentations to pneumothorax (a collapsed lung from air in the chest) and chylothorax discovered during acute evaluation. In the months covered, these single-case experiences show pleural complications can strongly affect symptoms and may need individualized procedures, while the evidence remains limited because it is case-based.

Research covered in: July 2026, September 2026

Walking distance repeatedly diverged from FEV1 change patterns.

Early in 2026, a registry analysis (a study using data collected in a patient registry) found that shorter 6-minute walk distance (a timed walking test of functional capacity) separated people into groups with different survival outcomes. In that analysis, walk distance did not predict the future rate of FEV1 decline (forced expiratory volume in 1 second, a common breathing test). Later case-based follow-up reinforced that different measures can move in different directions over time. This included long-term sirolimus-treated twins with generally stable lung function but declining walking distance. A separate sirolimus cohort also reported a small early rise in FEV1 at 12 months with longer-term stability, while non-lung outcomes changed more clearly. In the months covered, these reports support tracking function (like walking distance) because it can reflect day-to-day impact and risk information that may not mirror spirometry trends.

Research covered in: January 2026, May 2026, June 2026

Reports emphasized pattern-based diagnosis and limits of single tests.

In the months covered, reports more clearly stressed that diagnosing LAM works best by putting several pieces together. This includes confirming true cysts on CT (computed tomography, a detailed X-ray scan), recognizing CT patterns and extra-pulmonary clues (findings outside the lungs), and using VEGF-D (a blood marker linked to lymphatic activity) as supportive evidence rather than a single rule-in/rule-out test. Real-world data showed VEGF-D was usually higher in definite LAM than in look-alike conditions. However, a minority of people with otherwise typical LAM features still had VEGF-D below a commonly used cutoff. A separate case report described elevated VEGF-D in a person ultimately diagnosed with Birt-Hogg-Dube syndrome (a genetic condition that can also cause lung cysts). Tissue studies and pathology series added that some markers may be more consistently positive than others in subtle lesions (e.g., consistent TSC2 loss/cathepsin K; GPNMB staining in all 17 LAM biopsies studied), while HMB-45 could be focal and GPNMB had interpretation pitfalls. In the months covered, this helps explain why diagnosis can take more than one test, and why tissue or genetic confirmation may be needed when results do not line up.

Research covered in: February 2026, April 2026, May 2026, June 2026, July 2026, September 2026